Compare Cintas Corporation (CTAS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Incyte Corporation — how do they compare? Cintas Corporation trades at $202.61 (market cap $79.86B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Cintas Corporation is far larger — about 3.5× Incyte Corporation's market cap, and Cintas Corporation pays a 1.03% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 125 Days and Incyte Corporation for 33 Days on average.
| CTAS | INCY | |
|---|---|---|
Market Cap | $79.86B | $22.85B |
Volume | 1,323,583 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $216.53 | $129.93 |
52-Week Low | $163.55 | $83.80 |
Typical Hold Time | 125 Days | 33 Days |
Enterprise Value | $82.33B | $18.35B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $202.41, up 2.65% on the day, reflecting strong momentum after recent earnings beat. The stock exhibits a bullish technical setup with price above key moving averages. Fundamentally, the company reported Q1 2027 revenue of $3.01 billion, a 10.9% YoY increase, with earnings per share of $1.39 surpassing estimates. Robust profitability is evident with a net income margin of 17.82% and ROE of 41.25%. Recent news highlights raised fiscal 2027 guidance, signaling management confidence in continued growth driven by organic expansion and margin gains.
The outlook for CTAS remains positive, supported by consistent revenue growth, high profitability, and bullish analyst sentiment with a consensus price target of $234.60. Key opportunities include sustained demand for uniform rental and workplace services, while risks involve elevated valuation multiples and potential economic sensitivity. The stock's current trajectory suggests further upside if execution remains strong, though investors should monitor margin sustainability and competitive pressures.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
